All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

NKX019 Showcases Manageable Safety, Early Activity in R/R B-cell Non-Hodgkin Lymphoma

July 27th 2023

The allogeneic natural killer cell therapy NKX019 was found to have an acceptable toxicity profile and to induce deep and durable responses in patients with relapsed or refractory B-cell non-Hodgkin lymphomas.

Social Determinants of Health Correlate With Lower CRC Screening Rates

July 26th 2023

Isabelle Franklin discusses the effects of social determinants of health on rates of colorectal cancer screening, expands on how these social determinants of health could affect a patient’s likelihood of adhering to screening guidelines, and highlights ways to potentially address these barriers to screening.

Expanding Definitions of HER2 Expression Mediate the Role of ADCs in Breast Cancer

July 26th 2023

Erika P. Hamilton, MD, discusses the role of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer; the evolution of CDK4/6 inhibitors in hormone receptor–positive disease; and how genetic testing can match patients with personalized therapies and support further precision medicine research.

Gaps in Validated Quality Indicator Use Are Evident in Active Surveillance of Low-Risk Prostate Cancer

July 26th 2023

Varied levels of compliance were observed in terms of using validated quality indicators to determine the quality of active surveillance for patients with low-risk prostate cancer, according to findings from a population-based study published in the Journal of the Comprehensive Cancer Network.

mRNA-4157 Plus Pembrolizumab Under Further Investigation in Phase 3 Trial in High-Risk Melanoma

July 26th 2023

The combination of mRNA-4157 and pembrolizumab will be further evaluated as an adjuvant treatment option for patients with resected, high-risk, stage IIB to IV melanoma in the phase 3 V940-001 trial.

First Patient Treated with Genetically Modified T-Cells Developed at state’s only National Cancer Institute-designated Comprehensive Cancer Center

July 26th 2023

Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center together with RWJBarnabas Health, has treated its first patient using genetically modified T-cells that were manufactured in its own state-of-the-art Good Manufacturing Practices facility, a fully commissioned clean space for manufacturing of viral vectors and cell products for human administration.

NCCN Adds Flotufolastat F 18 Injection to Clinical Practice Guidelines for Prostate Cancer

July 26th 2023

The National Comprehensive Cancer Network has added flotufolastat F 18 injection to its Clinical Practice Guidelines in Oncology for positron emission tomography of prostate-specific membrane antigen–positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy.

FDA Clears Investigational New Drug Application for TCR-NK Cell Therapy in Multiple Myeloma

July 26th 2023

The FDA has issued a ‘safe to proceed’ for the investigational new drug application enabling a phase 1 study evaluating NY-ESO-1 TCR/IL-15 NK, a first-in-class engineered T-cell receptor natural killer cell therapy for patients with relapsed/refractory multiple myeloma.

Birtamimab Pushes the Needle in AL Amyloidosis

July 26th 2023

Findings from an analysis of treatment patterns for patients with systemic amyloid light chain amyloidosis have demonstrated that several unmet needs exist, including timely diagnosis and limited survival outcomes for patients with advanced disease.

Sugemalimab Plus Chemotherapy Yields Statistically Significant Improvement in OS and PFS in NSCLC

July 26th 2023

Sugemalimab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival vs placebo plus chemotherapy for the first-line treatment of patients with stage IV non–small cell lung cancer irrespective of PD-L1 expression level and tumor pathological type.

Selinexor Maintenance After First-Line Chemotherapy Extends PFS in TP53 Wild-Type Advanced Endometrial Cancer

July 25th 2023

Selinexor maintenance generated an improvement in progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer who responded to first-line chemotherapy.

Geriatric Oncology ASCO Guidelines Provide Update on Importance of Assessment

July 25th 2023

ASCO has released an update to the guidelines for the practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy.

Treatment Sequencing Clarifications May Spur NSCLC Therapeutic Evolutions

July 25th 2023

Angel Qin, MD, contextualizes the non–small cell lung cancer ADAURA trial, in which patients with EGFR-mutated non–small cell lung cancer who received adjuvant therapy with osimertinib achieved a 5-year overall survival rate of 85% vs 73% in those who received placebo.

Missing a Rare Cause of Hereditary Cancer

July 25th 2023

New research from Cedars-Sinai Cancer investigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common cause of hereditary colorectal and endometrial cancers.

BMF-219 Demonstrates Early Activity in Menin-Dependent AML

July 25th 2023

Oral treatment with BMF-219 led to 2 complete responses of 5 patients with relapsed/refractory acute myeloid leukemia with menin-dependent mutations, both of which remain on treatment.

IDMC Recommends Continuation of PANOVA-3 Trial of TTFields in Unresectable, Locally Advanced Pancreatic Cancer

July 25th 2023

An independent data monitoring committee has recommended the continuation of the phase 3 PANOVA-3 trial evaluating tumor treating fields in combination with nab-paclitaxel and gemcitabine for the treatment of patients with unresectable, locally advanced pancreatic cancer.

First-Line Rivoceranib Plus Camrelizumab Improves Survival in Unresectable HCC

July 25th 2023

Treatment with the combination of rivoceranib and camrelizumab led to a statistically significant and clinically meaningful benefit in progression-free survival and overall survival compared with sorafenib in previously untreated patients with unresectable hepatocellular carcinoma.

Advances in Early-Stage Breast Cancer Pull Biology and Biomarkers Into Focus

July 25th 2023

As new data emerge in breast cancer, stepping back from the updates and shedding light on the standard practices as they exist in the clinic are crucial approaches to management of the disease.

Gilead Discontinues Phase 3 ENHANCE Trial of Magrolimab/Azacitidine in Higher-Risk MDS

July 25th 2023

The phase 3 ENHANCE trial evaluating the first-line combination of magrolimab and azacitidine vs placebo plus azacitidine in patients with higher-risk myelodysplastic syndrome has been discontinued due to futility at a planned analysis.

Tinengotinib Elicits Clinical Benefit in Pretreated Cholangiocarcinoma and Other Advanced Solid Tumors

July 24th 2023

Sanjay Goel, MD, MS, expands on the findings from the phase 1b/2 trial, noting the potential benefit this approach may have for patients with cholangiocarcinoma, and detailed next steps for investigating tinengotinib.